These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38367816)

  • 1. Comprehensive phenotypic and genomic characterization of venous malformations.
    Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
    Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic landscape of common venous malformations in the head and neck.
    Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
    J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
    Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
    Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
    Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
    Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
    Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
    Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
    Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
    Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
    Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
    Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A xenograft model for venous malformation.
    Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
    Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations.
    Nozawa A; Fujino A; Yuzuriha S; Suenobu S; Kato A; Shimizu F; Aramaki-Hattori N; Kuniyeda K; Sakaguchi K; Ohnishi H; Aoki Y; Ozeki M
    J Hum Genet; 2022 Dec; 67(12):721-728. PubMed ID: 36171295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional assessment of two variants of unknown significance in TEK by endothelium-specific expression in zebrafish embryos.
    Bell LM; Holm A; Matysiak U; Driever W; Rößler J; Schanze D; Wieland I; Niemeyer CM; Zenker M; Kapp FG
    Hum Mol Genet; 2021 Dec; 31(1):10-17. PubMed ID: 34254124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
    Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
    J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for capillary-venous malformations.
    Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
    Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Molecular Therapies for Venous Malformations.
    Kangas J; Nätynki M; Eklund L
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.
    Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H
    Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
    Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
    EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
    Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
    Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.